Quartz 4

Research: Investigate Asahi's Proprietary Ingredients under EU Novel Food Regulations

6 min read

Research: Investigate Asahi’s Proprietary Ingredients under EU Novel Food Regulations

Asahi’s Proprietary Ingredients under EU Novel Food Regulations

Overview

As part of its strategic diversification and expansion into the global health and wellness sector, [[asahi-group-holdings]] has accelerated the commercialization of its proprietary functional ingredients across international markets. Guided by its 2024–2027 health and wellness rollout plan, the conglomerate is utilizing its R&D expertise in lactic acid bacteria and yeast to capture market share in [[adult-soft-drinks]], dietary supplements, and functional foods [12]. Navigating the European market requires strict compliance with [[novel-food-regulations]] set forth by the [[european-commission-ec]] and evaluated by the [[european-food-safety-authority-efsa]].

Note: The ingredient and beverage initiatives of Asahi Group Holdings discussed here are entirely separate from [[asahi-kasei]], which is a distinct materials and healthcare conglomerate operating in Europe [9].

Core Proprietary Ingredients

Lactobacillus gasseri CP2305

The flagship functional ingredient driving Asahi’s European expansion is [[lactobacillus-gasseri-cp2305]]. Discovered through decades of research into the lactic acid bacteria used in [[calpis]], CP2305 is a paraprobiotic (or postbiotic) material [1, 6]. Because the bacteria are heat-killed, the ingredient provides exceptional formulation stability, bypassing the stringent cold-chain requirements typically associated with live probiotics and making it highly viable for [[functional-premiumization]] in RTD beverages and baked goods [3, 11].

Backed by at least eight human clinical trials, CP2305 has demonstrated efficacy in modulating the gut-brain axis [3]. Scientifically validated benefits include:

  • Alleviating psychological and mental stress [2, 4].
  • Enhancing the depth and quality of sleep [2, 4].
  • Improving intestinal health and bowel habits [2].
  • Mitigating mood swings, mental fatigue, and drowsiness associated with premenstrual phases and menopausal symptoms [2, 12].

In late 2025, CP2305 received the “Health Innovation Award” at Food Ingredients Europe in Paris and the “Functional Ingredient of the Year” at Gulfood Manufacturing in Dubai, underscoring its broad market applicability [2, 3].

Additional Strains and Compounds

  • Yeast Mannan: [[yeast-mannan]] is another proprietary material currently being researched and commercialized by Asahi for its potential to improve bowel habits and sleep quality [12].
  • Lactobacillus acidophilus L-92: Utilized in the “PLUS Calpis” concentrated beverage line in Japan, this strain is marketed for immune support and relieving seasonal nasal discomfort [4].

The commercialization of non-traditional ingredients in the European Union is strictly governed by [[novel-food-regulations]], which stipulate that any food not significantly consumed in the EU prior to May 15, 1997, must undergo a rigorous safety assessment before entering the market [7].

Taxonomic Revisions and Regulatory Exemptions

The regulatory pathway for [[lactobacillus-gasseri-cp2305]] in the EU is deeply intertwined with recent taxonomic revisions in microbiology. While novel extractions or genetically modified microorganisms require extensive pre-market authorization, specific traditional strains are exempt.

Recently, the [[european-commission-ec]] updated the Novel Food Catalogue to include Lactobacillus paragasseri. Previously considered a subspecies of L. gasseri, L. paragasseri was recognized as an independent species following modern taxonomic revisions [7]. The Commission determined that this microorganism was used in food supplements prior to the May 15, 1997 threshold [7]. Consequently, it is not classified as “novel” and circumvents the lengthy [[novel-food-regulations]] approval procedure, provided standard quality and labeling requirements are met [7].

Furthermore, the broader species Lactobacillus gasseri is recognized by the International Dairy Federation as having a safe history of use in fermented milk and sourdough dating back to 1980 [8]. This historical precedent eases the regulatory burden for Asahi’s CP2305 compared to entirely novel botanicals or adaptogens, allowing it to bypass some of the rigid hurdles that contribute to the [[clinical-substantiation-gap]] often seen with newer functional ingredients.

Contrasting Frameworks: EU vs. US FDA

Unlike the EU’s date-based Novel Food system, the US regulatory framework relies on the [[gras-generally-recognized-as-safe]] designation administered by the [[fda]]. Competing L. gasseri strains (such as BNR17 by Chr. Hansen) have achieved GRAS status, indicating a favorable regulatory environment for Asahi’s global distribution efforts [8].

Global Commercialization and B2B Strategy

To rapidly scale its health and wellness portfolio, [[asahi-group-foods]] transitioned from localized domestic sales to a global B2B distribution model.

In February 2025, Asahi signed an exclusive distribution agreement with [[adm-wild-valencia]] (ADM) [1, 10, 12]. Under this agreement, Asahi retains domestic usage rights for its internal beverage and supplement lines, while ADM leverages its global supply chain to market and distribute [[lactobacillus-gasseri-cp2305]] to third-party food and beverage manufacturers across North America, Europe, and Asia [1, 2].

This B2B expansion directly supports Asahi’s entry into the burgeoning [[adult-soft-drinks]] market in the US and the UK. By supplying functional postbiotics that target the “relaxation” and “low-calorie” mega-trends, Asahi aims to capture consumers shifting away from traditional alcohol [12].

Contradictions and Research Gaps

  • Taxonomic Ambiguity in Filings: The sources highlight the taxonomic split between L. gasseri and L. paragasseri and its implications for EU Novel Food exemptions [7]. However, it is not explicitly clear from the available public search data whether Asahi’s specific CP2305 strain has been officially reclassified under the newly exempt L. paragasseri label, or if it relies on the broader historical safety dossier of L. gasseri.
  • Beverage vs. Supplement Classification: While CP2305 is heavily utilized in dietary supplements in Japan, its regulatory classification in the EU when suspended in [[adult-soft-drinks]] may trigger distinct enforcement frameworks, highlighting the ongoing [[beverage-vs-supplement-ambiguity]].

Suggested Additional Sources

To fully map Asahi’s compliance footprint, future research should target:

  1. EFSA Scientific Opinions: Official [[european-food-safety-authority-efsa]] scientific opinions specific to Lactobacillus gasseri CP2305 to verify its exact Novel Food status and approved health claims under the EU Register of nutrition and health claims.
  2. French DGCCRF Bulletins: Documentation from the French Directorate General for Competition, Consumer Affairs and Fraud Repression, which reportedly authorized specific gut flora claims for L. paragasseri [7], to see if ADM/Asahi explicitly utilize this ruling.
  3. Cross-Reference with [[functional-beverage-regulations]]: Comparative analysis of CP2305’s compliance costs versus the regulatory friction surrounding botanical adaptogens (e.g., Ashwagandha) in the EU market.

References

  1. ADM and Asahi Group Sign Exclusive Distribution Agreement for … — adm.com
  2. Asahi Group’s Lactobacillus gasseri CP2305 Wins Functional … — asahigroup-holdings.com
  3. ADM’s Lactobacillus gasseri CP2305 Wins Functional Ingredient of the Year at Gulfood Manufacturing | ADM — adm.com
  4. HPA (China) News - October 2025 - International Probiotics Association — ipa-biotics.org
  5. Summary of applications and notifications — food.ec.europa.eu
  6. Regulatory effect of paraprobiotic Lactobacillus gasseri CP2305 on gut environment and function - PMC — pmc.ncbi.nlm.nih.gov
  7. Lactobacillus paragasseri is added to the European Union’s Novel Food Catalogue — belabservices.com
  8. [PDF] GRAS Notice 1089, Lactobacillus gasseri strain NCIMB 30370 … - FDA — fda.gov
  9. European locations - Asahi Kasei — asahi-kasei.eu
  10. How Is Japan’s Postbiotic Food Supplement Market Expanding — openpr.com
  11. [PDF] RESEARCH AND DEVELOPMENT — asahigroup-holdings.com
  12. Asahi lays out plans for global rollout of health and wellness business — nutraingredients.com

Graph View